Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.APP Pharmaceuticals, a Fresenius Kabi Company, has announced the launch of both Imipenem and Cilastatin for Injection, USP and Meropenem for Injection, USP in the US.
Subscribe to our email newsletter
The company will begin the shipment of Meropenem for Injection in 500mg and 1gm single dose vials from 13 February 2012.
The Imipenem and Cilastatin for Injection in 250mg and 500mg single dose vials will be made available in the next three to five weeks, the company said.
Imipenem and Cilastatin for Injection is therapeutically equivalent to the reference-listed drug Primaxin IV, which is currently marketed by Merck.
Meropenem for Injection is therapeutically equivalent to the reference-listed drug Merrem IV, currently marketed by AstraZeneca Pharmaceuticals.
APP Pharmaceuticals president and CEO John Ducker said the upcoming launch of these two products marks APP’s entry into the Carbapenem market.
"Adding these two products to our portfolio further strengthens our existing anti-infective line and helps solidify our continued leadership in the reliable supply of sterile generic injectables," Ducker added.